10x Genomics, Inc. (TXG) [Rocket]

In millions, except per share items	Mar-31-23	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21	Dec-31-20
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Revenue	134.3	114.6	114.5	143.5	125.3	115.8	105.8	112.2
Revenue growth	17.3%	-1.1%	8.2%	27.9%	74.5%	170.0%	47.2%	49.0%
Cost of revenue	35.9	27.7	25.5	27.6	24.5	4.9	17.1	18.9
Gross profit	98.4	86.9	89.0	115.9	100.8	110.9	88.8	93.3
Gross margin	73.3%	75.8%	77.7%	80.8%	80.4%	95.8%	83.9%	83.2%

Operating expenses:
Research and development	67.1	70.7	64.1	61.9	54.6	53.4	41.9	39.7
Selling, general and administrative	83.3	79.3	66.7	69.9	62.1	68.7	56.9	56.0
Total operating expenses	150.4	150.0	130.8	263.5	116.7	243.4	99.0	502.9
Loss from operations	-52.0	-63.1	-41.7	-15.8	-15.9	-10.3	-10.2	-409.6
Operating margin	-38.7%	-55.1%	-36.5%	-11.0%	-12.7%	-8.9%	-9.7%	-365.0%

Other income (expense):
Interest income	3.9	1.2	0.6	0.0	0.0	0.1	0.1	0.1
Interest expense	0.0	-0.1	-0.1	-0.2	-0.2	-0.2	-0.2	-0.3
Other expense, net	-1.5	-1.8	-0.4	0.0	-0.6	0.5	-0.7	1.2
Total other income	2.3	-2.6	-0.4	-0.2	-0.8	0.9	-0.9	2.3
Loss before provision for income taxes	-49.7	-63.8	-41.7	-16.0	-16.6	-10.0	-11.1	-408.6
Provision for income taxes	1.1	0.6	0.7	2.5	0.5	1.1	0.4	7.0
Net loss	-50.7	-64.5	-42.4	-18.4	-17.2	-11.1	-11.6	-415.6

Net loss per share, basic (in dollars per share)	($0.44)	($0.57)	($0.38)	($0.17)	($0.15)	($0.10)	($0.11)	($4.09)
Net loss per share, diluted (in dollars per share)	($0.44)	($0.57)	($0.38)	($0.17)	($0.15)	($0.10)	($0.11)	($4.09)

Weighted-average shares of common stock used in computing net loss per share, basic	115.6	113.6	113.0	110.3	110.9	109.9	108.7	101.2
Weighted-average shares of common stock used in computing net loss per share, diluted	115.6	113.6	113.0	110.3	110.9	109.9	108.7	101.2